Long-term follow-up of gene therapy for Leber congenital amaurosis
Part of Eyes & vision, Genetic & congenital clinical trials.
This study is a long-term follow-up for people who already received the LX101 gene therapy in an earlier trial for Leber congenital amaurosis (LCA), a rare inherited eye disease that causes severe vision loss. It aims to see how safe and effective the treatment is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the original LX101 gene therapy study for Leber congenital amaurosis (LCA).
- You cannot have had any serious side effects from the gene therapy during the original study.
- You cannot have other eye conditions (like glaucoma, cornea problems, or severe cataracts) that could interfere with the treatment or study results.
- You must not have had any eye surgery in the 6 months before joining.
- You must be able to follow the long-term follow-up schedule and use effective birth control if you are able to have children.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests the safety of putting a gene medicine into the eye for people with vision loss caused by LCA5 gene mutations. It includes a treatment group and a separate group of people who do not receive the gene medicine during the study.
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
This trial tests a one-time gene therapy given under the retina to treat a rare inherited eye disease that causes poor vision. It may help slow down vision loss or improve sight.
This trial tests a gene therapy called LX109 for wet age-related macular degeneration (AMD), a condition where abnormal blood vessels damage the retina. The therapy aims to reduce the need for frequent eye injections by providing a longer-lasting treatment.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This study tests an investigational RNA therapy called sepofarsen for people with Leber Congenital Amaurosis (LCA) type 10, a rare inherited eye disease that causes severe vision loss from birth. The goal is to see if it can slow or improve vision loss.
Hear when a new To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.